MaaT013

· MaaT Pharma

Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for MaaT013, covering 2024-08-28 to 2024-10-17. Get the full timeline:

Most recent: Clinical Trial Update: MaaT013 As Salvage Therapy in Ruxolitinib Refractory GI-aGVHD Patients [Phase 3]